BBP-418
BridgeBio Pharma (BBIO)
Decision dateNov 27, 2026
12 days away
Marketer take
Potential first therapy in a very small neuromuscular population, where patient identification and specialist outreach drive launch.
- Sponsor company
- BridgeBio Pharma (BBIO)
- Indication
- Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)
- Therapeutic area
- Neurology, Rare disease
- Event
- PDUFA target action date
- Date
- Nov 27, 2026
- Status
- Upcoming
- Source
- company press release
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?